Key insights
- Citizens reiterates a Market Outperform rating on CRISPR Therapeutics (CRSP), citing positive developments in gene editing for cardiovascular disease. Data presentations and capital inflows into related companies suggest strong interest in the approach. While the stock may be overvalued according to some analysis, the firm's $80 price target reflects confidence in future developments. CRSP also recently priced a larger-than-expected convertible note offering.
Investing.com - Citizens reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) shares. The stock currently trades at $51.59, suggesting potential upside of roughly 55% to the analyst’s target. Wall Street consensus points to even greater upside of 47%, with analyst targets ranging from $33 to $291.
The firm maintains a positive view on in vivo editing in cardiovascular disease. Data presentations at the ongoing European Atherosclerosis Society Congress are drawing interest in gene editing approaches to dyslipidemias and cardiovascular disease, according to Citizens.
The analyst highlighted updates from Eli Lilly/Verve, Editas, and other organizations that have led to capital inflows into cardiovascular gene therapy companies. New modalities that can deliver more profound and sustained lipid lowering and address adherence are of interest, the firm said.
Citizens believes these developments indicate clear interest in the opportunity and approach, which should benefit CRISPR Therapeutics and several closely related programs. The firm views the data presentations as derisking these approaches. Notably, 11 analysts have revised their earnings upwards for the upcoming period, according to an InvestingPro tip, though the company isn’t expected to be profitable this year.
The firm maintains its $80 price target, derived from discounted cash flow analysis, ahead of developments expected in the second half of 2026 and 2027. Investors should note that InvestingPro analysis suggests the stock may be overvalued at current levels. For deeper analysis, a comprehensive Pro Research Report is available, offering expert insights on CRSP alongside 1,400+ other US equities.
In other recent news, CRISPR Therapeutics announced the pricing of $550 million in convertible senior notes due 2031, which was an increase from the initially planned $350 million. The company has also granted initial purchasers the option to buy an additional $50 million in notes. This move follows the issuance of $600 million in convertible notes with a conversion rate of $76.56 per share and an effective coupon of 1.73%, as noted by Piper Sandler, which raised its price target for CRISPR Therapeutics to $110 and maintained an Overweight rating. The firm estimates that CRISPR Therapeutics now holds pro forma cash of $2.56 billion. Meanwhile, BofA Securities adjusted its price target for the company to $83 from $86, maintaining a Buy rating, and noted the company’s strong balance sheet following the convertible issuance. These developments are part of CRISPR Therapeutics’ ongoing financial strategies and have drawn attention from financial analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates CRSP alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if CRSP is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?